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there were 233 dystonia cases (mean age = 61 ± 13 years, 82 males/151 females), 1337 PD cases (mean age = 71 ± 10 years, 836 males/501 females) and 1090 controls (mean age = 70 ± 10 years, 530 males/560 females). This included 226 PD cases and 228 controls from our initial study [2] . Supplementary Table 1 summarises the demographics of these groups (Supplementary File). Blood was collected from all subjects and DNA extracted by standard methods.
Assays for the three GCH1 SNPs from our previous study -rs12147422, rs3759664 and rs10483639 -were designed and performed using the MassARRAY genotyping platform (Sequenom). We also designed and carried out genotyping assays for rs8007267 and rs3783641 to complete the pain-protective GCH1 haplotype [3] .
Genotyping was carried out on all subjects in this study. Reliability of genotyping was verified by re-genotyping a random selection of 16% of all subjects and also by comparing with our previously obtained genotypes [2] . No conflicts between our previous and current studies were discovered, and in total 98.6% of genotypes were successfully called. Statistical analyses were carried out in PLINK version 1.07 (http://pngu.mgh.harvard.edu/~purcell/plink/). The odds ratios (ORs) for genotype associations (additive model) were calculated using logistic regression with adjustment for age and gender.
Modest associations were seen in our original case-control series of 226 PD cases and 228 age-and gender-matched controls as previously reported [2] (Table 1 ). These associations were not observed in second series of 1105 PD cases and 862 controls, nor were they seen when both studies were combined into a single dataset (P > 0.05; Table 1 ).
Our initial study also comprised 230 isolated dystonia cases [2] . As only an additional three isolated dystonia cases were recruited into this study, we decided to analyse all M A N U S C R I P T
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233 cases against each control group (Table 2) . Similarly to our previous study, associations between GCH1 SNPs and isolated dystonia were found when comparing to the original control group (P < 0.05), but were not replicated when comparing this case group against either the second control series or all controls combined ( Table 2) .
We also looked at the "pain protective" haplotype comprised of rs10483639, rs3783641 and rs8007267, denoted in this study as the "H2" haplotype. No significant differences in haplotype frequencies were observed when comparing all PD cases or all dystonia cases to all controls individuals (Supplementary Table 2 , Supplementary File).
We previously determined that an additional 770 cases and controls would be needed to conclusively determine if our initial results were real and not spurious findings [2] .
The study we present here exceeds this requirement and has 90% power to detect ORs of at least 1.390 for the PD analysis and ORs of at least 1.700 for the isolated dystonia analysis, taking multiple testings into consideration. However, we were unable to replicate our original findings in this larger sample. Additionally, when we measured GCH1 expression in patient-derived cell lines cultured in identical conditions, no differences were observed between PD cases and controls (Supplementary File). This suggests that GCH1 SNPs do not alter susceptibility to PD. This is consistent with previously published literature regarding GCH1 variants in PD [5] .
Excluding our original analysis, there have been no other studies examining GCH1 genetic variants in idiopathic dystonia. While our analysis would have benefitted from the recruitment of additional dystonia cases, this was not possible as the low prevalence of the disorder suggests that we have likely included most of the available cases in Queensland. As we have previously stated, the rarity of the dystonia phenotype requires collaborative efforts for sufficiently large genetic association M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT studies [2] . In this study, we attempted to address this limitation by the addition of larger control group. However, the lack of reproducability in our analysis here suggests that the associations reported in our original study were spurious results.
This lends supports to the conclusions of our previous study that susceptibility to idiopathic dystonia is not greatly affected by common genetic variants around dystonia-linked genes. Taken with our original analyses, this highlights the need to expand the search for candidate genes for idiopathic dystonia. and incubated at 37°C with 5% CO 2 . Cell lines were grown in these conditions until at least 80% confluent and harvested by enzymatic detachment.
Cell lines were seeded into 6-well plates at a density of 40000 cells/well in 2 mL of medium and allowed to attach overnight. The media was replaced the following day with 2 mL of fresh media containing 100 ng/mL γ-irradiated lipopolysacchrides (LPS) from Salmonella enterica serotype typhimurium (Sigma Aldrich; Catalogue# L6143) and incubated for 6 hours.
mRNA expression
Whole cell RNA was extracted using the TRIzol method (Invitrogen). TRIzol-extracted RNA quality was assessed using a NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies) and a Agilent 2100 Bioanalyzer (Agilent Technologies). Total RNA was reverse transcribed using the SuperScript III first-strand synthesis kit with oligo(dT) 18 primers (Invitrogen). Relative levels of mRNAs were calculated and normalised against RPL32 using the ∆∆CT relative quantification method with correction for amplification efficiency [5] .
PCRs were carried out using the Corbett Rotor-Gene 6000 Real-Time PCR system (Qiagen) and the Sensimix HRM Master Mix (Bioline). PCR conditions were 95°C for 10 minutes followed by 50 cycles at 95°C for 10 seconds, 60°C for 15 seconds and 72°C for 20 seconds.
Melting curves were generated following amplification to confirm a single PCR product. 
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Control transcript selection
Transcripts that were consistently upregulated following treatment of cell lines with LPS were selected from microarray datasets and served as positive controls for LPS stimulation. These datasets encompassed several studies examining the transcriptional response to LPS treatment. In total, 8 microarray datasets were selected from public repositories and were used for determining appropriate control transcripts (Supplementary Table 1 ).
Probesets were considered for control gene selection if they met the following criteria: (1) linearised fold change greater than 3 in all datasets examined; (2) expressed in greater than
50% of all samples in all datasets examined; (3) expressed in the hONS cell lines at baseline
as per ArrayExpress studies E-TABM-724 [4] and E-TABM-879 [3] . Overall, 25 probesets were consistently upregulated across all datasets examined and 7 of these were expressed in the hONS cell lines (Supplementary Table 2 ) and from this list assays were designed to amplify three RefSeq transcripts: NM_001024465 (SOD2), NM_000963 (PTGS2), NM_000584 (IL8).
GCH1 mRNA expression in hONS
We then examined if GCH1 was differentially expressed between PDs and controls using hONS cell lines. These are human-derived cell lines cultured from biopsies of the olfactory neuroepithelium [6] , and provide a useful cell model system in which to study diseasespecific transcriptional differences in human neurological disorders, including PD [3, 4] . stimulated by the addition of LPS into culture medium, and transcriptional differences between carriers and non-carriers of the functional "pain protective" haplotype are observable following treatment [7] . As these studies have largely utilised immune and other bloodderived cell lines, we reviewed microarray data to select transcripts that could be used as positive controls for LPS treatment (see Supplementary File for dataset selection, normalisation and analysis). From these datasets we selected transcripts of three genes (PTGS2, IL8 and SOD2) that were consistently upregulated following LPS stimulation in several independent studies. We also selected the LAPTM4A transcript from these same datasets as a negative treatment control as its expression was relatively stable across these studies.
To demonstrate the responsiveness of the hONS cell lines to LPS treatment, we measured the gene expression after 6 hours of treatment with 100ng/mL LPS. GCH1, IL8, PTGS2 and SOD2 were all significantly upregulated, whereas LAPTM4A expression was unchanged, consistent with a response to LPS (Figure 2 ). We then compared the expression of GCH1 after LPS treatment between PD and control hONS cell lines and found no significant differences in GCH1 expression ( Figure 2 ). When cell lines were regrouped according to whether or not they carried the "pain protective" haplotype, the mean GCH1 expression was slightly lower in the haplotype carriers but this difference did not reach statistical significance 
